The holdings in Alexion Pharmaceuticals, AnorMED, Crucell, Forest Labs, OSI
Pharmaceuticals, Sirna Therapeutics and Targeted Genetics were reduced in size.
International Biotechnology Trust plc
Unaudited Preliminary Results
Unaudited Statement of Total Return (incorporating the Revenue Account)
For the year end 31 August 2003
For the year end 31 August 2002
Revenue Capital Total Revenue Capital Total
£'000 £'000 £'000 £'000 £'000 £'000
Gains/(losses) on
investments
7,613
7,613
(49,532)
(49,532)
Exchange
gains/(losses) on
currency balances
53
53
(28)
(28)
Income
112
112
278
278
Management fees
(638)
(638)
(804)
(804)
Administrative
expenses
(488)
(488)
(758)
(758)
Net (deficit)/return on
ordinary activities
before taxation
(1,014)
7,666
6,652
(1,284)
(49,560)
(50,844)
Tax on ordinary
activities
Net (deficit)/return on
ordinary activities
after taxation
(1,014)
7,666
6,652
(1,284)
(49,560)
(50,844)
Transfer (from)/to
reserves
(1,014)
7,666
6,652
(1,284)
(49,560)
(50,844)
(Deficit)/surplus per
share
(2.09)p
15.82p
13.73p
(2.64)p
(101.94)p
(104.58)p
The revenue column of this statement is the profit and loss account of the Company.
All revenue and capital items in the above statement derive from continuing operations.
